Roche stock heads into the open after a Lunsumio study win

At the close on September 16, 2026, Roche stock had already climbed 0.7 percent in SIX trading to CHF 363.00. The move came after Roche said its CELESTIMO phase III study met its primary endpoint, and the SMI stood at 13,868.66.

Roche stock closed at CHF 363.00 on the SIX on September 16, 2026, up 0.7 percent. Roche Holding (ISIN CH0012032048) also traded near the SMI's 13,868.66 close in the same session.

September 16, 2026 in numbers

As finanzen.ch reported on September 17, 2026, Roche said its phase III CELESTIMO study for Lunsumio met its primary endpoint, with progression-free survival improving versus the comparator. The stock finished the previous session at CHF 363.00 after rising 0.7 percent, and the SMI closed at 13,868.66.

The report also said Roche will submit the data to health authorities and present them at a future medical meeting. The session close gave the share a gain of CHF 2.60 from the prior move cited in the market report.

Today on September 17, 2026

Roche has already issued the CELESTIMO update before the US open. The release is the main company-specific item for today and may keep attention on the shares in Zurich trading.